AZD0156: Selective ATM Kinase Inhibitor for Cancer Research

Executive Summary: AZD0156 is an orally bioavailable, potent, and highly selective small-molecule inhibitor of ataxia telangiectasia mutated (ATM) kinase, a serine/threonine kinase in the phosphatidylinositol 3-kinase-related kinase (PIKK) family (APExBIO product page). The compound exhibits sub-nanomolar inhibitory potency against ATM with >1000-fold selectivity over other PIKK enzymes (Chen et al., 2020). ATM is essential for DNA double-strand break detection and repair, checkpoint control, and genomic stability regulation. Preclinical research demonstrates that AZD0156 enhances antitumor efficacy when combined with DNA-damaging agents and is under early clinical evaluation for advanced cancers. AZD0156 is supplied by APExBIO with ≥98% purity, and optimal results require appropriate storage and handling conditions.

Biological Rationale

Ataxia telangiectasia mutated (ATM) kinase is a central regulator of the DNA damage response (DDR), specifically in detecting and repairing DNA double-strand breaks (DSBs) via homologous recombination (HR) (Chen et al., 2020). Germline mutations in ATM cause ataxia telangiectasia (A-T), a disorder characterized by genomic instability and increased cancer risk. In high grade serous ovarian cancer (HGSOC), ATM is often wildtype and its expression is frequently upregulated, correlating with poor prognosis. Many tumors rely on efficient DNA repair pathways for survival, making ATM a rational target for therapeutic intervention in HR-proficient cancers that are resistant to PARP inhibitors or platinum-based regimens. Inhibition of ATM disrupts checkpoint control and impairs cellular responses to genotoxic stress, sensitizing cancer cells to DNA-damaging agents. Thus, selective ATM inhibition is a strategic approach to modulate DDR and enhance cancer therapy efficacy.

Mechanism of Action of AZD0156

AZD0156 (CAS: 1821428-35-6) is a small molecule that binds to the ATP-binding site of ATM kinase, resulting in potent inhibition of ATM’s serine/threonine kinase activity. The compound displays sub-nanomolar potency in cellular ATM signaling assays (APExBIO). Selectivity profiling shows >1000-fold reduced activity against other PIKK family kinases, including ATR and DNA-PKcs (related article). This high selectivity allows precise modulation of ATM-dependent DNA damage responses without off-target effects on related kinases. Upon DNA double-strand break induction, ATM autophosphorylates and phosphorylates downstream substrates such as Chk2, p53, and H2AX. AZD0156 blocks these phosphorylation events, impairing cell cycle checkpoint activation, DNA repair, and promoting apoptosis in cancer cells exposed to genotoxic stress. The inhibitor is orally bioavailable and achieves effective concentrations in preclinical tumor models, enabling combinatorial strategies with DNA-damaging chemotherapeutics or metabolic modulators.

Evidence & Benchmarks

• AZD0156 demonstrates sub-nanomolar inhibitory activity (IC₅₀ < 1 nM) against ATM kinase in enzyme and cellular assays (APExBIO).
• AZD0156 exhibits >1000-fold selectivity for ATM over ATR and DNA-PKcs in biochemical profiling (AZD0156: Potent, Selective ATM Kinase Inhibitor for DNA D...).
• In HGSOC cell models, ATM inhibition synergizes with fenofibrate (PPARα agonist) to induce cellular senescence, indicating a link between DNA repair and metabolic pathways (Chen et al., 2020).
• Preclinical studies show AZD0156 enhances the efficacy of DNA-damaging agents (e.g., irradiation, PARP inhibitors) in multiple cancer models (Chen et al., 2020).
• Clinical evaluation of AZD0156 in combination with DNA damaging agents is ongoing in patients with advanced cancers (NCT02588105, clinicaltrials.gov).

Applications, Limits & Misconceptions

AZD0156 is primarily used in research to dissect ATM-mediated DNA damage responses, checkpoint control, and therapeutic sensitization to DNA-damaging agents. It is especially valuable for studying HR-proficient cancers resistant to standard treatments. The compound’s specificity makes it suitable for mechanistic studies on genomic stability and cell fate regulation (AZD0156: A Selective ATM Kinase Inhibitor Redefining Canc...). This article updates prior reviews by integrating recent insights on metabolic pathway modulation and combinatorial strategies.

Common Pitfalls or Misconceptions

• Monotherapy limitations: AZD0156 alone typically does not induce significant tumor regression; it is most effective in combination with DNA-damaging or metabolic agents (Chen et al., 2020).
• Not a pan-PIKK inhibitor: The compound does not inhibit ATR, DNA-PKcs, or mTOR at relevant concentrations, making it unsuitable for studies targeting these kinases (related article).
• Inapplicability in ATM-deficient cells: Cells lacking functional ATM do not respond to AZD0156, so it should only be used in ATM-wildtype models (Chen et al., 2020).
• Solution stability: AZD0156 solutions are unstable over long periods; prepare fresh solutions and use promptly (APExBIO).
• Water insolubility: The compound is insoluble in water; dissolve in DMSO (≥23.1 mg/mL with gentle warming) or ethanol (≥5.49 mg/mL) for optimal results.

Workflow Integration & Parameters

For laboratory use, AZD0156 (B7822) is supplied as a solid with ≥98% purity (HPLC, NMR) by APExBIO. Dissolve in DMSO with gentle warming to achieve concentrations ≥23.1 mg/mL. Store powder at -20°C. Avoid repeated freeze-thaw cycles and do not store solutions long-term. For in vitro assays, typical working concentrations range from 0.01–1 μM depending on cell type and experimental design. In vivo, oral dosing regimens should be optimized based on preclinical pharmacokinetics and target engagement data. Combine with DNA-damaging agents, irradiation, or metabolic modulators for maximal efficacy in HR-proficient cancer models. For comparative protocols and troubleshooting, see AZD0156: Selective ATM Inhibitor for Cancer Research Work...; this article clarifies recent benchmarks and expands integration parameters for metabolic studies.

Conclusion & Outlook

AZD0156 is a benchmark tool for dissecting ATM kinase function in DNA damage response, checkpoint control, and metabolic adaptation in cancer research. Its exceptional selectivity and bioavailability enable precise experimental and translational studies targeting genomic stability. Ongoing clinical trials will further define its therapeutic value, especially in combination with DNA-damaging and metabolic agents. APExBIO provides validated, high-purity AZD0156 for advanced research workflows. For further reading on metabolic integration, see AZD0156: Insights into ATM Kinase Inhibition and Metaboli...; this article extends prior reviews by focusing on experimental best practices and combinatorial strategies in cancer therapy research.